Ennogen, a U.K.-based drug and device maker, reeled in a £30 million ($37.5 million) credit facility that the company will use to expand its international horizons. Santander U.K. is behind the loan ...

In an ongoing battle for dominance in the eyes of healthcare professionals for their work developing heart disease-focused drugs, Novartis has now snatched the top spot from Pfizer, according to a ...

Madrigal also expects to reinforce Rezdiffra’s clinical profile—and potentially convert the current accelerated approval to a full nod—with patient outcomes data from the MAESTRO-NASH trial. That ...

Even after consumer outfit Kenvue split from Johnson & Johnson one year ago, the company has been performing certain services for the pharma and medtech giant as part of a transition process. | Kenvue ...

After a 2023 approval from the FDA, Krystal Biotech has collected more than $95 million from its launch of Vyjuvek, the first treatment for the rare skin disease dystrophic epidermolysis bullo | The ...

In its opening months, after spinning off as a separate business from Novartis, Sandoz is riding the wave of a strong launch of its biosimilar version of AbbVie’s Humira (adalimumab). | After spinning ...

While cystic fibrosis has long been Vertex Pharmaceuticals’ bread and butter, the company has been eager to diversify its revenue base in recent years. As several patients start their treatment ...

As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the ...

Sharp, a subsidiary of Ireland’s UDG Healthcare, is honing its edge in the growing sterile injectables market by ...

Following Nucleus RadioPharma’s 2022 debut, the GE HealthCare- and Mayo Clinic-backed radiopharmaceuticals CDMO is ready to put its production thesis to the test. | Nucleus on Tuesday revealed that it ...

Amneal Pharmaceuticals has agreed to pay $272.5 million to settle approximately 900 lawsuits brought by state, local and ...

Zydus Lifesciences recently received its second Form 483 reprimand from the FDA within the span of one month. In the second ...